Trial Profile
A Randomized Double-Blind Phase III Study of RAD001 10mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In The Treatment Of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine carcinoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms RADIANT-3
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 15 Apr 2021 Results of post hoc pooled analysis from RADIANT-3 and RADIANT-4, published in the Cancer.
- 12 Oct 2017 Results of pooled data assessing effectiveness of sunitinib and everolimus in patients with pancreatic neuroendocrine tumours from two trial (RADIANT-3 and A6181111 ), were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 12 Sep 2016 Results of final overall survival and biomarker analysis published in the Journal of Clinical Oncology.